Tarsus 10-Q: Q3 XDEMVY Sales $194.6M, $668.3M Net Loss on $632.2M IPR&D Charge
TARS sits 37% above its 52-week low of $53.89.
Summary
Tarsus' Q3 10-Q shows XDEMVY sales of $194.6M (+64%) and a $668.3M net loss driven almost entirely by $632.2M of non-cash acquired IPR&D from the Alkeus and iRenix deals, with $309.6M of cash and at least 12 months of runway.
Key Events · Earnings and Guidance · TARS
-
XDEMVY Sales Grow 64% to $194.6M
Q3 2026 net product sales rose to $194.6 million from $118.7 million a year earlier on higher volume and improved gross-to-net discounts, at a 93% gross margin.
-
Net Loss Is Non-Cash IPR&D
The $668.3 million quarterly net loss includes $632.2 million of acquired IPR&D expense — $551.2 million from Alkeus and $81.0 million from iRenix — a non-cash charge tied to the acquisitions, not a cash outflow.
-
Cash of $309.6M, 12-Month Runway
Cash, cash equivalents and marketable securities totaled $309.6 million at September 30, 2026; management says this funds planned operations for at least 12 months, excluding any contingent milestone payments.
-
Deal Consideration and Contingent Liabilities
Alkeus total consideration was $577.3 million including $230.5 million of stock and $238.2 million cash, plus roughly $87.3 million of contingent consideration; iRenix cost $35.2 million cash plus 607,093 shares worth $40.7 million.
Analysis · TARS · Life Sciences
The headline loss is an accounting event, not a cash event: $632.2M of the $668.3M quarterly net loss is non-cash acquired IPR&D written off at closing for Alkeus ($551.2M) and iRenix ($81.0M). Strip that out and the commercial business is growing — XDEMVY net sales rose to $194.6M from $118.7M a year earlier at a steady 93% gross margin, and the company still generated $30.6M of operating cash flow over nine months. What actually matters for the thesis is the balance sheet: $309.6M of cash and securities against a $75.0M Pharmakon term loan, with management affirming at least 12 months of runway — but that runway explicitly excludes the large contingent milestones from the two deals, which would be significant cash calls if triggered. The stock's reaction will hinge on whether investors treat the loss as noise and focus on the sales trajectory and pipeline readouts (TP-04 Kore and TP-05 Calliope topline in 1H 2027, IRX-101 Comfort Phase 3 starting 1H 2027).
How filings like this one have moved
In the 30 days to Nov 4, 2026, 41.4% of the 1217 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TARS was trading at $74.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $53.89 to $91.53. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.